Featured Stories

Whole-Body Composition Assessment in Rodents

01/19/2015

In the treatment of clinical obesity, preclinical outcomes of adiposity remain critical to advancing the right drug candidate. However, there is much more to it than the scale.

Working Together to Accelerate Vaccine Development

01/07/2015

Charles River has been supporting the development of new vaccines and drugs to protect against deadly diseases for decades. And now, more than ever, our scientific experts are working together with our sponsors to accelerate this research.

New ÄKTA™ avant Systems Arrive

01/02/2015

Charles River has recently added four new ÄKTA™ avant chromatography units to the existing selection of chromatography equipment at our viral clearance facility located in King of Prussia, PA, USA. This recent investment provides additional capacity for the execution of viral clearance studies at Charles River. 

Introducing Expanded Program Management Team

12/29/2014

By tapping into our scientific excellence and regulatory knowledge, you get cost-effective, fully integrated programs tailored to your specific needs. Our scientific program managers leverage our full range of services and best-in-class expertise to design your optimum program and ensure that it is completed on time and within budget.

Expanding to Meet Your Needs

12/23/2014

Charles River is pleased to announce the addition of a workspace dedicated to GMP-compliant in vivo potency/immunopotency testing at our in vivo biosafety testing facility in Wilmington, MA, USA.

CiPA: A New Day for Cardiac Safety Assessment

12/16/2014

Advances in our understanding of the role of cardiac ion channels in arrhythmogenesis, and newly available in vitro technologies, has prompted implementation of a new strategy for identifying cardiac risk during drug development.

ADCP: The Neglected Mechanism of Action

12/05/2014

In vitro antibody-dependent cellular phagocytosis (ADCP) assays based on primary macrophages as effector cells are excellent tools to establish the in vivo mechanism of action (MOA) of a therapeutic monoclonal antibody (mAb) during the early phase of drug development.

Displaying results 1-10 (of 139)
 |<  < 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10  >  >|